Minoxidil 3 Months In: What the Week 12 Trial Data Shows

What does minoxidil 3 months in actually show?

In the trials, an effect was usually measurable by weeks 12 to 16 but rarely visible. In 404 women on once-daily 5% foam, hair counts were 10.9 hairs per cm² higher than on vehicle at week 12, a gap no smaller than at week 24. The new hairs start soft, fine and often colourless, so a hair count can show a change before a mirror does. The men's 5% label says results may appear at 2 months, some men need at least 4, and to stop use and ask a doctor if there is no regrowth in 4 months.

Reaching minoxidil 3 months in is often when doubt peaks. The shed, if there was one, is fading. The routine is a habit. And the mirror looks the same. In a 99-patient clinic survey, people who gave up on topical minoxidil had used it for a median of three and a half months, and half of them said the reason was no improvement (Senthilnathan et al, J Drugs Dermatol 2023, PMID 36877874).

That study cannot say whether those patients would have responded later. What the trials can say is more specific: what minoxidil does to a measured patch of scalp by week 12, and why that change usually doesn't show up in a bathroom mirror yet.

Below: what the trials counted at weeks 12 and 16, the growth arithmetic behind the lag, the first-month shed, the product label's checkpoints, and what month three is useful for. The main focus is topical 5% minoxidil, the form sold over the counter. Oral minoxidil gets its own section, because it is prescribed off label and runs on a different evidence base.

Table of contents

• Minoxidil 3 months in: what the trials counted
• Why minoxidil at 3 months can look like nothing
• Month 1 on minoxidil: the shed and what it does and does not mean
• Where month three sits against the label's checkpoints
• Month three is a good time to review side effects
• Oral minoxidil at 3 months
• What month three is useful for
• What changes between month three and month six
• Frequently Asked Questions

Minoxidil 3 months in: what the trials counted

The two large foam trials measured hair counts at weeks 12 and 16, and at those timepoints the counts had already moved clearly compared with vehicle. That makes minoxidil's early evidence different from finasteride's. In the finasteride registration trials, hair counts were not reported before month six. Minoxidil's trials give more to go on at month three.

Trial	Who and what	Earliest efficacy timepoint	What it found
Bergfeld et al, J Drugs Dermatol 2016	404 women, 5% foam once daily vs vehicle foam	Week 12	+10.9 hairs/cm² over vehicle at week 12, +9.1 at week 24 (both p<.0001). Total hair width per cm² also up at week 12
Olsen et al, J Am Acad Dermatol 2007	352 men, 5% foam vs placebo	Week 16 (no efficacy data after that)	Hair counts and self-assessment both significantly better than placebo (p<.0001). A later review reports target-area counts up 13.4% vs 3.4% on placebo (Int J Trichology, PMC2938579)
Hillmann et al, Skin Pharmacol Physiol 2015	70 men, 5% foam twice daily on front and crown vs placebo foam	Up to week 16, then week 24	Counts rose significantly from baseline up to week 16. At week 24, hair width at the front beat placebo, but the hair-count comparison was not significant
Olsen et al, J Am Acad Dermatol 2002	393 men, 5% vs 2% solution vs placebo, twice daily	Interim visits, main result at week 48	"Response to treatment occurred earlier with 5%" than with 2%, per the hair count data

Two things stand out in that table.

First, the women's foam trial. The gap over vehicle at week 12 was 10.9 hairs per cm². At week 24 it was 9.1. At group level, in that trial, most of the measured separation from vehicle was already there by month three. That is a single trial of once-daily foam in women, so it does not map directly onto men using the solution twice a day. It is still the clearest published answer to "has anything happened by now?"

Second, the men's front-and-crown trial. Hair counts rose significantly from each man's own baseline up to week 16. By week 24 the count gap against placebo foam was not significant, though hair width at the front was. A within-person gain at month three is therefore not proof of a drug effect on its own. Placebo arms can gain something too: in the 352-man foam trial, counts on placebo rose 3.4%. That is why a trial needs a control group and why a single person's photos can mislead in either direction.

All of these figures come from a small marked target area, counted under magnification by trained staff. The minoxidil results hub covers the six-month and one-year numbers. Month three is only the first stretch of that curve.

Why minoxidil at 3 months can look like nothing

A measurable change at week 12 and an unchanged mirror are consistent with each other, because the first hairs minoxidil produces are the hardest kind to see. The US leaflet for men's 5% foam says it plainly: "At first, hair growth is usually soft, downy, colorless hairs (like peach fuzz). After further use, the new hairs should be the same color and thickness as the other hairs on your scalp" (DailyMed, men's 5% foam).

The same leaflet gives the growth-rate reason: "normal hair usually grows only 1/2 to 1 inch per month". A follicle that starts a new growth cycle in the second month has had a few weeks to produce a short, fine, pale hair by the end of the third. Among thousands of existing hairs, that is invisible from arm's length.

The trials show the same thing from another angle: early change is partly in thickness, not only in number. In the women's foam trial, total hair width per cm² rose by 658 micrometres more than vehicle at week 12, about the same as at week 24. In a small 96-week study of 36 men, Price et al (J Am Acad Dermatol 1999, PMID 10534633) found that minoxidil raised hair weight by about 30% over baseline, while hair counts "were usually less significant". Weight and width track fullness. They are also hard to capture in a photo taken under bathroom light.

So no visible change at month three is not a verdict. A visible change isn't guaranteed later either. It means month three is too early for a mirror to settle the question.

Month 1 on minoxidil: the shed and what it does and does not mean

A temporary increase in shedding early on is described on the product label and has been measured in one study. It is not universal, and three sources give three different time windows.

Source	What it says about the early shed
US leaflet, men's 5% foam	Hair loss "may increase temporarily for up to 2 weeks". If it "continues after two weeks, see your physician"
Bi et al, J Dermatolog Treat 2025, PMID 40122142	49 patients, counts every four weeks for 24 weeks: a temporary increase within the first 12 weeks, lasting longer on 2% than on 5%
Reviews summarised on the minoxidil results hub	Short-term shedding reported during roughly the first eight weeks for some users. Many do not notice it

The label's two weeks is the shortest window. Bi's twelve weeks is the only one based on counting hairs at intervals. Those are different kinds of evidence, and a leaflet written for self-care is designed to be conservative. The label's instruction still stands: shedding that continues past two weeks is a reason to talk to a physician. That conversation may simply confirm the diagnosis.

Does a shed predict success? In Bi's 49 patients, a bigger peak in shedding was linked to more improvement in hair-loss grade. That is a retrospective association in a small group, not a rule. Some people who respond well never notice a shed. Having no shed at month one is not a bad sign, and a heavy one is not a guarantee.

Some shedding shouldn't be put down to minoxidil at all. The US labels tell people not to use the product if hair loss is sudden or patchy, if there is no family history of hair loss, if the reason is unknown, or if the scalp is red, inflamed or painful (DailyMed, men's 5% solution). Loss like that during the first three months calls for an examination rather than patience. If you are unsure whether your pattern fits, the Norwood stage finder takes about two minutes.

Where month three sits against the label's checkpoints

The over-the-counter labels give a specific checkpoint for each product, and month three sits before both of them. For men that means one month early; for women on once-daily foam, three months early.

Product	"Results may occur at"	"Some need at least"	Stop and ask a doctor if no regrowth by
Men's 5% solution, twice daily	2 months	4 months	4 months
Men's 5% foam, twice daily	2 months	4 months	4 months
Women's 5% foam, once daily	3 months	6 months	6 months
AAD patient guidance	"Usually about 6 to 12 months" to see results

The wording comes from the current DailyMed labels for the men's solution, the men's foam and the women's foam.

Read together, these sources don't conflict. The label's "may occur at 2 months" is the earliest point anyone might notice something. The four-month stop-and-ask point is the product's own safety net: an over-the-counter drug is telling the user when to bring in a doctor. The AAD's six to twelve months describes when dermatologists expect visible regrowth in practice. None of them makes month three a pass-or-fail point for men. For women on foam it is exactly the label's "may occur" point, and still three months before its stop-and-ask point.

What comes after the four-month check without regrowth is covered in minoxidil not working: the diagnosis questions, the non-responder evidence and why published response rates range so widely. None of it overrides the label: at four months without regrowth, the next step is a doctor, not more product.

Month three is a good time to review side effects

Tolerability, unlike results, can be judged by month three: three months of daily use is long enough to know whether the scalp tolerates the product. With the results still unclear, it is the question month three answers best.

Effect	Reported rate	Source
Scalp itching and local irritation	More frequent on 5% than 2% solution	Olsen 2002, 393 men
Itching, 5% foam	1.1%, against about 6% in a separate trial of 5% solution	Manufacturer-affiliated review, PMC2938579; indicative only
Unwanted facial or body hair, women	4% of 1,333 women across placebo-controlled trials (all arms, placebo included), dose related	Dawber and Rundegren, J Eur Acad Dermatol Venereol 2003
Systemic effects at topical doses	No evidence of systemic effects in the 48-week solution trials	Olsen 2002, 393 men; Lucky 2004, 381 women

The labels list the systemic warning signs that mean stopping and seeing a doctor: chest pain, rapid heartbeat, faintness or dizziness, sudden unexplained weight gain, or swollen hands or feet. They are rare with topical use, but they are the signs to know. The same labels say to ask a doctor before use if you have heart disease, and that the product may be harmful if used when pregnant or breast-feeding.

Two findings matter for anyone thinking about switching products at month three. Persistent itching or flaking on the 5% solution is often put down to its propylene glycol, which the foam leaves out. But a systematic review of 99 patch-test-confirmed allergy cases found minoxidil itself was the allergen in 74.7% and propylene glycol in 17.1% (PMID 38885151). Switching to foam helps some people and not others, and patch testing can show which. The practical differences are covered in minoxidil foam vs solution.

The other point is about pets. The labels say to keep the product out of reach of children and pets, and a 2025 scoping review collected published cases of minoxidil poisoning in cats and dogs (McMullen et al, J Am Acad Dermatol 2025, PMID 40189148). Cats are the main concern: 10 of the 68 cats in those reports died, and cats were mostly exposed indirectly, by licking treated skin or lying on contaminated bedding. The case figures, along with the rest of the three-tier breakdown, are in minoxidil side effects.

Oral minoxidil at 3 months

Oral minoxidil is a prescription blood-pressure tablet whose US label carries a boxed warning about serious heart effects at blood-pressure doses. It is not FDA-approved for hair loss and is prescribed off label, so it has no label timeline for hair. The month-three picture comes from the prescriber's plan and from trials that measured at six months. In a double-blind randomised trial comparing 5 mg oral with 5% topical (90 men enrolled, 68 completed), run at one Brazilian clinic in men at Norwood 3 vertex to 5 vertex, efficacy was judged at week 24. Oral was not superior overall: it was better on crown photographs, with no significant difference on the hair-density endpoints (Penha et al, JAMA Dermatol 2024, PMID 38598226).

The side-effect data are more useful at month three. A large retrospective safety series of 1,404 patients (two thirds of them women, with any type of alopecia) who had all taken low-dose oral minoxidil for at least three months recorded, across 2,469 dose episodes:

• unwanted hair growth (hypertrichosis) in 15.1%
• lightheadedness in 1.7%
• fluid retention in 1.3%
• a fast heart rate in 0.9%

1.7% of patients stopped because of side effects, and no life-threatening events were observed. The study had no control group, so these are reported rates, not rates caused by the drug over placebo (Vañó-Galván et al, J Am Acad Dermatol 2021, PMID 33639244). At the higher 5 mg dose in the Penha trial, 22 of 45 men (49%) reported hypertrichosis and 14% headache.

That sets the agenda for a month-three review of oral treatment. Swelling of the ankles or around the eyes, palpitations, dizziness on standing and new body hair all belong in that conversation. Hair results mostly don't yet. Dose and monitoring are the prescriber's decision; the trade-offs are set out in oral minoxidil for hair loss.

What month three is useful for

Month three can't judge results, but it is the right time to check the things that will decide whether a result shows up later. Four checks, each with its reason:

1. The baseline photo. Without matched before-and-after photos, the four- and six-month comparisons are guesswork. If there was no day-one photo, a month-three photo in fixed conditions is the next best baseline: same light, same camera distance, dry hair of the same length, same parting.
2. Where the product goes. The foam leaflet stresses applying it "directly to your scalp and not to your hair". Product that dries on the hair shafts never reaches a follicle. It also says "using more than the recommended amount will not improve results".
3. How many doses were actually used. In the clinic survey above, 35% of the non-adherent patients had used minoxidil for less than three months, against 3% of the adherent ones. Missed doses and weekend gaps are worth counting honestly, because a partial course can't be judged against trial results.
4. Whether the diagnosis still fits. Minoxidil works on pattern hair loss. The men's foam leaflet says it won't help loss from thyroid disease, severe iron deficiency, some medicines or scarring conditions. Month three is a reasonable time to confirm the diagnosis, especially if the loss is spreading outside the usual pattern.

One point on changes. Adding or switching treatments at month three resets the comparison, because the next set of photos will reflect two changes at once. Anyone thinking about adding finasteride, switching form or adjusting a dose can raise that with a prescriber, who can plan the timing. How the two drugs compare is covered on the finasteride vs minoxidil page.

What changes between month three and month six

Months four to six are when the label checkpoints fall and when the evidence first begins to line up with what you might see. The women's foam trial measured its main result at week 24. The pivotal solution trials followed men and women to week 48, with 5% solution giving 45% more regrowth than 2% in men at that point. The hub linked above sets out each milestone.

Stopping has a timeline too. The men's foam leaflet says anyone who stops "will lose your newly regrown hair in 3 to 4 months". In Price's 96-week study, once treatment stopped, hair weight and counts fell back to about placebo levels within 24 weeks. Stopping at month three costs little in regrowth, since there is little yet. It also leaves the question of whether minoxidil works for that person unanswered.

That is why month three matters for a decision. It is too early to judge results and early enough that stopping gives up little. In the clinic survey above, people who stopped had done so after a median of three and a half months, a few weeks before the men's label checkpoint at four months.

Frequently Asked Questions

Is it normal to see no results from minoxidil at 3 months?

Yes, for many users. The men's 5% labels say results may occur at 2 months but some men need at least 4, and the AAD puts visible regrowth at about 6 to 12 months. Trials did detect hair count changes by weeks 12 to 16, but those were small counts in a marked target area, and the leaflet says early regrowth is usually soft, fine and colourless. The label's own checkpoint is four months for men and six for women using once-daily foam.

Is shedding at 3 months normal on minoxidil?

Early shedding is described, but the time windows vary. The men's foam leaflet says up to two weeks, and to see a physician if it continues longer. One 49-patient study measured a temporary increase within the first 12 weeks, lasting longer on 2% than on 5%. Heavy, patchy, painful or sudden loss at any point should be examined rather than assumed to be minoxidil.

What does minoxidil regrowth look like at 3 months?

According to the product leaflet, early regrowth is usually "soft, downy, colorless hairs (like peach fuzz)" that thicken and darken with continued use. Trials also measured increases in hair width and hair weight, which make hair look fuller, not only more numerous. Neither shows up well in casual photos, which is why matched photos under fixed lighting matter.

What happens if I stop minoxidil after 3 months?

Any hair gained or held by minoxidil is gradually lost. The men's foam leaflet says new regrowth is lost within 3 to 4 months of stopping, and a 96-week study found hair measures back near placebo levels within 24 weeks. Stopping at month three also means not reaching the four-month point the label uses to judge the product. A dermatologist or prescriber can help weigh that against side effects or the ongoing cost.

---

Month three is around when many people give up on minoxidil, and it is too early to judge it. A dermatologist, GP or prescribing clinician who can examine the scalp is the right person to confirm the diagnosis, review side effects and set the date for a fair comparison.